May 22, 2026, NCHR submitted comments to NIH on their draft of resources needed for investigational implantable device trials, emphasizing the need for better planning to make sure that patients understand the medical and financial risks of having an experimental implant that may be found to be neither safe nor effective. Patients volunteering for clinical trials of implanted devices deserve to know the risks and be protected from long-term device-related risks and medical care.
Read More »Author: Caroline Bradford
Testimony of Dr. Diana Zuckerman at the FDA Oncology Drugs Advisory Committee on TRUQAP
FDA Oncology Advisory Committee on TRUQAP, April 30, 2026: NCHR president Dr. Diana Zuckerman expressed her concerns about the serious risks and uncertain benefits of TRUQAP given that there is no evidence that it improves overall survival
Read More »Testimony of Dr. Diana Zuckerman at the FDA Oncology Drugs Advisory Committee on Breast Cancer
FDA Oncology Advisory Committee, April 30, 2026: NCHR president Dr. Diana Zuckerman expressed her concerns about uncertain evidence in the SERENA-6 trial of camizestrant in patients with ER+HER2 advanced breast cancer in combination with a CDK4/6 inhibitor plus aromatase inhibitor upon detection of an ESRI biomarker.
Read More »NCHR Written Comment to AHRQ on Improving the Management of Menopausal Symptoms in Perimenopausal and Early Postmenopausal Women
May 13, 2026, NCHR submitted comments in response to AHRQ’s request for feedback on its research protocol that will inform the NIH Pathways to Prevention Workshop on Improving the Management of Menopausal Symptoms. NCHR urged AHRQ to include all relevant studies rather than exclude foundational evidence through publication date cutoffs. We are especially concerned at the exclusion of long-term Women’s Health Initiative (WHI) findings, and to provide unbiased, easy-to-understand information about the risks and benefits of different menopause treatments.
Read More »Next FDA chief to face similar headwinds after Makary’s ouster
The Hill, May 14, 2026: The next FDA Commissioner will face the same MAHA-MAGA challenges that Marty Makary did, including political interference, funding cuts, and White House interference. NCHR President Diana Zuckerman notes that although Makary offended just about everybody, he lost his job over a few actions (or lack of actions) that the White House did not like, and urges a more scientific, evidence-based FDA rather than one that bends to political appointees, donors, and friends of the White House.
Read More »